Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 4/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28996924 | 1.00 | TGM2 (0.56) | TGM2TRPV1EGFRTEAD1KDR | |
| SCHEMBL28997013 | 1.00 | TGM2 (0.56) | TGM2TRPV1EGFRTEAD1KDR | |
| SCHEMBL25413281 | 0.91 | TGM2 (0.56) | TGM2TRPV1EGFRTEAD1 | |
| SCHEMBL28996943 | 0.90 | EGFR (0.49) | TGM2TRPV1EGFRKDRTEK | |
| SCHEMBL30357001 | 0.90 | EGFR (0.49) | TGM2TRPV1EGFRKDRTEK | |
| SCHEMBL26126243 | 0.90 | EGFR (0.49) | TGM2TRPV1EGFRKDRTEK | |
| SCHEMBL29369433 | 0.90 | EGFR (0.49) | TGM2TRPV1EGFRKDRTEK | |
| SCHEMBL28996911 | 0.90 | EGFR (0.49) | TGM2TRPV1EGFRKDRTEK | |
| SCHEMBL30356990 | 0.90 | EGFR (0.49) | TGM2TRPV1EGFRKDRTEK | |
| SCHEMBL29370301 | 0.87 | TGM2 (0.54) | TGM2TRPV1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116057042-A | Acrylamide-substituted indane compounds and their therapeutic uses | 赛诺菲 | 2023-05-02 | — | — | CN | claimed |
| US-12441679-B2 | Acrylamide-substituted indane compounds and therapeutic use thereof | SANOFI (FR) | 2025-10-14 | — | — | US | disclosed |
| CN-116057042-B | Acrylamide-substituted indane compounds and their therapeutic uses | 赛诺菲 | 2024-10-18 | — | — | CN | disclosed |
| US-20230265047-A1 | Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof | SANOFI (FR) | 2023-08-24 | — | — | US | disclosed |
| EP-4188907-A1 | ACRYLAMIDE-SUBSTITUTED INDANE COMPOUNDS AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2023-06-07 | — | — | EP | disclosed |
| CN-116057042-A | Acrylamide-substituted indane compounds and their therapeutic uses | 赛诺菲 | 2023-05-02 | — | — | CN | disclosed |
| WO-2022023460-A1 | ACRYLAMIDE-SUBSTITUTED INDANE COMPOUNDS AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441679-B2 | Acrylamide-substituted indane compounds and therapeutic use thereof | IDH2, INA, IDH3A | TGM2 1405/4885TRPV1 1577/4885EGFR 631/4885 |
| US-20230265047-A1 | Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof | IDH2, INA, IDH3A | TGM2 1405/4885TRPV1 1577/4885EGFR 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.